Ovid Therapeutics Inc. 4
4 · Ovid Therapeutics Inc. · Filed May 10, 2017
Insider Transaction Report
Form 4
During Matthew
DirectorPresident and CSO10% Owner
Transactions
- Conversion
Series A Preferred Stock
2017-05-10−28,245→ 0 total→ Common Stock (28,245 underlying) - Conversion
Common Stock
2017-05-10+28,245→ 4,307,314 total
Holdings
- 93,023(indirect: By Trust)
Common Stock
- 93,023(indirect: By Trust)
Common Stock
- 93,023(indirect: By Trust)
Common Stock
- 93,023(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]The Series A Preferred Stock converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering, on a one-for-one basis and had no expiration date.